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SUMMARY 
Diversamente dal carcinoma duttale infiltrante (IDC) della mammella, per il 
carcinoma lobulare infiltrante (ILC) non sono ancora completamente noti quali 
siano i fattori patologici e molecolari che guidano la prognosi di questo istotipo.  A 
questo proposito, è necessario chiarire l'eventuale impatto prognostico e/o 
predittivo di potenziali drivers, al fine di studiare il background molecolare dei 
pazienti con ILC. Tra i fattori da esplorare, quello della proliferazione, 
comunemente valutata mediante l’antigene Ki67, rappresenta ad oggi un aspetto 
rilevante nella scelta del trattamento per il tumore della mammella in fase iniziale, 
in particolare nella malattia luminale. L’analisi condotta su una casistica 
retrospettiva multicentrica di 679 pazienti con istologia lobulare, in stadio iniziale 
e operati, confrontata con 418 pazienti con istologia duttale ha evidenziato che un 
valore del 4%-5% rappresenta il miglior cut-off di Ki67 in grado di distinguere tra 
pazienti affetti da ILC a prognosi favorevole o sfavorevole.  
Per quanto riguarda il ruolo della chemioterapia adiuvante ad oggi le principali linee 
guida non raccomandano un trattamento diverso in funzione dell’istologia, data 
l’assenza di studi randomizzati condotti nel ILC. Da analisi retrospettive emergono 
dati discordanti in merito al beneficio della chemioterapia adiuvante in aggiunta 
alla terapia ormonale per il ILC ad immunofenotipo luminale. A questo proposito, 
una differenza significativa in termini di sopravvivenza globale (OS) tra sola 
ormonoterapia e ormonoterapia più chemioterapia adiuvante (OS a 5 e 10-anni 
96.3% vs 86.0% e 92.2% vs 67.5%, rispettivamente) è stata evidenziata dalla nostra 
analisi condotta mediante ‘propensity score’ su 473 pazienti affetti da ILC luminale.  
Una delle principali strategie di ricerca emergenti in ambito oncologico si basa sullo 
studio del genoma di pazienti con risposta anomala al trattamento o con prognosi 
inattesa. Adottando questa strategia, abbiamo analizzato retrospettivamente una 
serie multicentrica di quasi 500 pazienti affetti da ILC sottoposti a resezione 
chirurgica e abbiamo costruito uno dei primi modelli di classificazione del rischio 
per ILC, successivamente convalidato in una coorte di 282 pazienti. Questo 
modello, basato su una combinazione di parametri semplici clinico-patologici, è 
stato in grado di stratificare in modo efficace i pazienti con ILC con una buona 
accuratezza prognostica. Una volta identificati i ‘migliori’ e ‘peggiori’ dal punto di 
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vista prognostico, abbiamo studiato il loro pattern molecolare, principalmente 
mediante sequenziamento genetico (NGS), e il loro profilo di espressione per 
identificare alterazioni molecolari ricorrenti ed esplorare la loro associazione 
prognostica in una coorte preliminare di 20 pazienti a buona prognosi e 14 a 
prognosi sfavorevole. In generale, il gene mutato più comunemente era il gene 
CDH1 (38,2%), seguito da PIK3CA (29,4%) e TP53 (20,6%), mentre la perdita di 
CDH1 (44,1%) e ARID1A (38,2%) sono state le variazioni del numero di copie più 
frequenti. Le alterazioni molecolari erano distribuite indipendentemente dalla 
prognosi, ad eccezione dell’aumento del numero di copie (gain) di CDK4, 
esclusivamente presente nel sottogruppo a prognosi sfavorevole (35.0%, p=0.03; 
Odds Ratio 7.98, 95%CI 1.51-42.1, p=0.014).  
Lo scopo ultimo del progetto era di valutare il profilo molecolare degli ILC 
resecabili utilizzando tecnologie moderne al fine di identificare quelle aberrazioni 
molecolari potenzialmente in grado di prevedere la probabilità di recidiva. Questa 
analisi integrata e multi-step eseguita ha suggerito che la via di CDK4/6 possa avere 
un impatto biologico rilevante sull’oncogenesi del ILC. Certamente, il carattere dei 
nostri dati, anche in considerazione della numerosità del campione, rappresenta 
un’ipotesi che deve essere prospetticamente validata in una serie di pazienti più 
estesa. 
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ABSTRACT 
Differently from invasive ductal carcinoma (IDC) of the breast, pathological and 
molecular factors that guide the prognosis of invasive lobular carcinoma (ILC) are 
not completely known. In this regard, the prognostic and/or predictive impact of 
potential drivers needs to be elucidated, in order to create a global portrait for ILC 
patients. Among these factors, the role of proliferation, commonly evaluated by the 
Ki67 antigen, represents a relevant aspect in the choice of adjuvant treatment for 
breast cancer, in particular in the luminal setting. This retrospective multicentric 
analysis, including 679 patients with early-stage resected lobular histology and 
comparing these with 418 patients affected by IDC, showed that a value of 4%-5% 
represents the best Ki67 cut-off of able to significantly discriminate the prognosis 
of patients affected by ILC.  
Regarding the role of adjuvant chemotherapy, to date the main guidelines do not 
recommend a different treatment approach according to histology, given the 
absence of randomized studies conducted in the ILC setting. From retrospective 
analyses, the benefit of adjuvant chemotherapy in addition to hormonotherapy for 
luminal ILC is still unclear. In this regard, our propensity score analysis conducted 
on 473 patients affected by luminal ILC showed a significant difference in terms of 
overall survival between hormonotherapy alone and hormonotherapy plus adjuvant 
chemotherapy (5- and 10-year 96.3% vs. 86.0% and 92.2% vs. 67.5%, 
respectively). 
Nowadays, one of the main emerging research strategies in cancer is based on the 
study of the genome of exceptional responder and prognostic ‘outlier’ patients. 
Adopting this strategy, we retrospectively analysed a multicenter series of nearly 
500 ILC patients underwent surgical resection and we built one of the first risk 
classification model for ILC, subsequently validated in a cohort of 282 patients. 
This model, based on a combination of simple and easily available clinical-
pathological parameters, was able to effectively stratify ILC patients in prognostic 
risk classes, with a good accuracy. Once identified the ‘best’ and ‘worst’ prognostic 
performers, we investigated their molecular portrait, principally by next-generation 
sequencing (NGS), and their expression profile to identify recurrent molecular 
alterations and explore their association with prognosis, in a preliminary cohort of 
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20 patients with good prognosis and 14 with poor prognosis. Overall, the most 
frequent mutated gene was the CDH1 gene (38.2%), followed by PIK3CA (29.4%) 
and TP53 (20.6%), while the loss of CDH1 (44.1%) and ARID1A (38.2%) were the 
most frequent copy number variation events. The molecular alterations were 
distributed regardless of the prognosis, except for the gain of CDK4, exclusively 
present in the poor prognosis subgroup (35.0%, p=0.03; Odds Ratio 7.98, 95%CI 
1.51-42.1, p=0.014). 
The final aim of the overall project was to evaluate the molecular profile of outliers 
resected ILC using modern technologies in order to identify those molecular 
aberrations that could potentially predict the probability of recurrence. This 
integrated and multi-step analysis suggested that the CDK4/6 pathway may have a 
significant biological impact on the ILC prognosis. Certainly, this hypothesis needs 
to be prospectively validated in a larger series.  
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INTRODUCTION 
Invasive lobular carcinoma (ILC), accounting for 5% to 15% of all invasive breast 
tumors, represents the second most common histologic type of breast cancer after 
invasive ductal carcinoma (IDC) [1, 2].  
The lobular histotype is generally characterized by luminal/HER2-negative 
phenotype and lower mitotic index, usually measured by the immunohistochemical 
assessment of the Ki67 antigen, and grading in comparison with IDC. Although 
these aspects are typically associated with a favorable prognosis, the overall long-
term survival of ILC appears worse than that of invasive carcinoma of NST [3]. 
Even the recent genomic characterization of ILC underlined that this histotype 
represents a peculiar entity of breast cancer [4-6]. 
However, despite the several dissimilarities between lobular and ductal histology in 
terms of clinical-pathological and molecular features, the prognostic and 
therapeutic aspects of ILC are currently borrowed from the ductal histotype, thereby 
limiting their clinical utility in the specific context of lobular subtype. In the 
adjuvant context, patients resected for early-stage breast cancer are assigned to 
receive hormonotherapy or chemotherapy according to international guidelines 
based upon immunophenotype, clinical-pathological and genomic features, 
regardless of the histotype [7]. Therefore, the identification of prognostic factors 
for ILC represents a relevant aspect for clinical practice in order to select 
appropriate treatment strategies.  
The preliminary stratification of patients according to prognosis may allow to 
identify those patients characterized by ‘best’ and ‘worst’ prognosis, emerging 
as ’outliers’, or rather biologically different from the majority of the population 
affected by the same biologically-defined disease. These ‘outlier’ patients may 
harbor a series of molecular aberrations potentially driving their peculiar clinical 
behavior. In this regard, the assignment of a reliable clinical significance to a 
specific genomic alteration, that can impact on patient prognosis and determine 
susceptibility to selective targeted therapies, represents a main challenge for recent 
translational research. This approach to selectively identify potential predictors of 
prognosis and (eventually) resistance or response to a given treatment in the context 
of ‘best’ and ‘worst’ prognostic performers, represents nowadays one of the strategy 
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that may successfully integrate the clinical findings with the advanced genetic 
acquisitions [8].  
In the recent era of personalized medicine, the identification of the appropriate risk 
category for each patient represents a promising strategy for two main reasons [8]. 
First, in the context of an early-stage disease, the prognostic stratification might 
allow selection of those patients with a more favourable risk-benefit ratio from 
adjuvant treatments. Second, from an exploratory point-of-view, the molecular 
characterization of patients featured by a different prognosis, by applying the 
modern technologies, could help in the identification of those genomic and 
epigenomic aberrations potentially able to predict the probability of disease 
recurrence (prognostic factors) and the efficacy of agents selectively targeting these 
candidate pathways (predictive factors). In this regard, the project aims to: 1) 
explore the prognostic role of Ki67 in the context of early-stage ILC and compare 
the optimal Ki67 cut-off for ILC with the optimal cut-off for IDC; 2) investigate the 
effect of adjuvant chemotherapy in the lobular histotype; 3) develop and validate a 
prognostic nomogram for early stage ILC patients, according to the combination of 
clinical-pathological predictors, in order to identify those prognostic ‘outliers’ 
candidate to undergo to genomic analysis. 
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MATERIAL AND METHODS 
The overall project included three main aims: 
1. Exploring the prognostic role of Ki67 for early-stage ILC and comparing 
the optimal Ki67 cut-off for ILC with the optimal cut-off for IDC.  
2. Investigation of the impact on survival of adjuvant chemotherapy in the 
lobular histotype. 
3. Building and validation of a clinical prognostic nomogram for early-stage 
ILC patients, according to the combination of clinical-pathological 
predictors, in order to identify those prognostic ‘outliers’ candidate to 
undergo to genomic analysis. 
1. Prognostic role of Ki67 for early-stage ILC and comparison of the optimal 
Ki67 cut-off for ILC with the optimal cut-off for IDC.  
Patients’ Population.  
Data of consecutive patients affected by early stage ‘pure’ ILC, undergone surgery 
at 3 Italian institutions (University of Verona and University of Padua providing 
data for the training set [TS] and Regina Elena National Cancer Institute (Rome) 
for the validation set [VS]) from January 1990 and December 2013, were 
considered eligible. These data were compared with clinical-pathological data of a 
consecutive series of patients affected by pure IDC and undergone surgery between 
2006 and 2010. Inclusion criteria were ‘pure’ ILC or IDC diagnosis (stage I-III), 
curative surgery and availability of clinical-pathological parameters (age, 
Performance Status, menopausal status, type of surgery, clinical stage, treatments, 
grading, Ki67, estrogen receptor, progesterone receptor, and HER2 status). The 
study was approved by the local Ethics Committee (Prot. CESC n° 24163, May 
20th, 2014).  
End-Points.  
The aims of this analysis were: 1) to identify the best prognostic cut-off of ki67 in 
terms of disease free survival (DFS) and overall survival (OS) for patients with 
resected ILC, comparing that with the best prognostic cut-off for patients with 
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resected IDC; 2) to investigate its impact in long-term outcome; 3) to validate the 
Ki67 cut-off for ILC in an external patients’ cohort. The DFS was defined by the 
time between diagnosis and local or distant recurrence, onset of secondary cancer 
or death for any cause and OS was defined by the time between diagnosis and death 
for any cause. 
Statistics.  
Descriptive statistic was adopted to summarize pertinent study information. 
Follow-up was analyzed and reported according to Shuster [9]. The maximally 
selected Log-Rank statistics analysis was applied to the Ki67 continuous variable 
in order to estimate the most appropriate cut-off values able to split patients with 
ILC and IDC diagnosis into groups with different DFS probabilities [10]. 
Associations between variables and groups according to Ki67 were analyzed (Chi-
square test). Clinical-pathological data were correlated to DFS and OS using a Cox 
model. The hazard ratio (HR) and the 95% Confidence interval (95% CI) were 
estimated using the Cox univariate model [11]. A multivariate Cox proportional 
hazard model was developed using stepwise regression (forward selection, enter 
limit and remove limit, p=0.10 and p=0.15, respectively), to identify independent 
predictors of outcomes in patients with ILC and IDC. The Harrell’s guidelines for 
the identification of the correct number of covariates were taken into account for 
the power analysis [12]. Outcomes calculated by the Kaplan–Meier product limit 
method. The log-rank test was used to assess differences between subgroups. 
Significance was defined at p<0.05.  
To address the multivariate model overfit, a cross-validation technique, which 
evaluates the replication stability of the final Cox model in predicting the outcomes, 
was investigated [13, 14].  
The Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was performed 
to evaluate whether the prognostic effect (in terms of DFS) between ILC and IDC 
varies according to the Ki67 [15].  
Finally, an external validation of the Ki67 cut-off for ILC patients was 
accomplished as well: the maximally selected Log-Rank statistics analysis was 
applied to the Ki67 values in the VS.   
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The SPSS® (18.0), R® (2.6.1), and MedCalc® (14.2.1) licensed statistical 
programs were used for all analyses. 
 
2. Investigation of the impact on survival of adjuvant chemotherapy in the lobular 
histotype. 
Patients’ Population.  
Data of consecutive patients affected by early stage ‘pure’ ILC, undergone surgery 
at 3 Italian institutions (University of Verona, University of Padua and Catholic 
University of the Sacred Heart Rome) between January 2000 and December 2013, 
were collected. Inclusion criteria were ‘pure’ ILC diagnosis (stage I-III), curative 
surgery and availability of clinical-pathological parameters (age, Performance 
Status, menopausal status, type of surgery, clinical stage, treatments, grading, Ki67, 
estrogen receptor, progesterone receptor, and HER2 status). 
End-Point.  
The aim of this analysis was to investigate the impact of the addition of adjuvant 
chemotherapy to hormonotherapy in patients affected by luminal early-stage pure 
ILC in terms of DFS, distant disease-free survival (DDFS) and OS. The DDFS was 
defined by the time between diagnosis and distant recurrence.  
Statistics.  
Descriptive statistic was adopted to summarize pertinent study information. 
Follow-up was analyzed and reported according to Shuster [9]. Clinical-
pathological data were correlated to DFS, DDFS and OS using a Cox model. The 
hazard ratio (HR) and the 95% Confidence interval (95% CI) were estimated using 
the Cox univariate model [11]. A multivariate Cox proportional hazard model was 
developed using stepwise regression (forward selection, enter limit and remove 
limit, p=0.10 and p=0.15, respectively), to identify independent predictors of 
outcomes. The Harrell’s guidelines for the identification of the correct number of 
covariates were taken into account for the power analysis [12]. A propensity score 
analysis was performed to evaluate the prognostic impact of adjuvant chemotherapy 
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[16]. Outcomes calculated by the Kaplan–Meier product limit method. The log-rank 
test was used to assess differences between subgroups. Significance was defined at 
p<0.05. The SPSS® (18.0), R® (2.6.1), and MedCalc® (14.2.1) licensed statistical 
programs were used for all analyses. 
3. Building and validation of a prognostic nomogram for early-stage ILC 
patients in order to identify those prognostic ‘outliers’ candidate to undergo to 
genomic analysis. 
Patients’ Population.  
Clinical charts of consecutive patients affected by early stage ILC diagnosed at 3 
Italian institutions (University of Verona and University of Padova providing data 
for the TS and University Federico II of Napoli for the VS) between January 1990 
to December 2013 were considered eligible. Inclusion criteria were ‘pure’ ILC 
diagnosis (stage I-III), curative surgery and availability of clinical-pathological 
parameters.  
End-Points.  
The aims of this analysis were 1) to develop a prognostic nomogram on the basis 
of clinico-pathological factors in a multi-center population of ILC (TS), in order to 
identify prognostic ‘outliers’; 2) to validate the model in an external patients’ cohort 
(VS); 3) to explore potential molecular drivers of prognosis with NGS in a subset 
of prognostic ‘outlier’ patients.    
Statistical Analysis.  
Descriptive statistics was used to summarize pertinent study information. Follow-
up was analyzed and reported according to Shuster et al [9]. Associations between 
variables were analyzed according to the Pearson χ2 test. The assessment of 
interactions between significant investigational variables was taken into account 
when developing the multivariate model. The Harrell’s guidelines for the 
identification of the correct number of covariates were taken into account for the 
power analysis (the number of deaths should have been more than 10 times greater 
than the number of investigated predictors, so that the expected error from the Cox 
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model would be less than 10%). The Kaplan-Meier product limit method was 
adopted for survival analyses. The HR and the 95% CI were estimated for each 
variable using the Cox univariate model [11]. The variables considered at univariate 
analysis included age, performance status, menopausal status (the postmenopausal 
status was defined as the absence of a menstrual period > 12 months, due to natural 
causes, or bilateral oophorectomy), type of surgery, clinical stage (tumor (T)-
category and nodal status), grading, Ki67, vascular invasion, estrogen receptor, 
progesterone receptor, and HER2 status. A multivariate hazard model was 
developed using the stepwise regression (forward selection, enter limit and remove 
limit, p=0.10 and p=0.15, respectively), to identify independent predictors of 
outcomes  [17]. The outcomes were DFS and OS. To address the multivariate model 
overfit, an internal cross-validation technique was performed [12-14, 18]. The 
internal validation analysis generates a number of simulation datasets (at least 100, 
each approximately 80% of the original size), by randomly selecting patients from 
the original sample, to establish the consistency of the model across less-powered 
patient’ samples. The log-rank test was used to assess differences between 
subgroups. Significance was defined at the p<0.05 level. The SPSS® (18.0), R® 
(2.6.1), and MedCalc® (14.2.1) licensed statistical programs were used for all 
analyses. 
Prognostic Score Assessment.  
A step-by-step protocol was followed according to the methodological approach for 
building a nomogram for cancer prognosis proposed by Iasonos et al. [14] with 
respect to the reporting recommendations for tumor marker prognostic studies 
(REMARK) criteria [19, 20]. The log-HR obtained from the Cox multivariate 
analysis was used to derive weighting factors of a continuous prognostic index, 
aimed to identify differential outcomes’ risks. Coefficients estimates were 
‘normalized’ dividing by the smallest one and rounding the resulting ratios to the 
nearest integer value. Thus, a continuous score assigning to patients an 
‘individualized’ risk was generated. To develop the prognostic model [21], patients’ 
outcomes were displayed by dividing patients into three risk classes, by considering 
cut-offs chosen at approximately equal distance along the range of values [22]. 
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Finally, an external validation of the DFS model was explored in the VS. The 
receiver operating characteristic analysis allowed to estimate the accuracy of the 
prognostic model, by the AUC) determination with SE.   
Samples and molecular analysis.  
Formalin-fixed and paraffin-embedded (FFPE) ILC samples from patients at poor 
prognosis (defined with the prognostic model) were selected from the University of 
Verona according to the availability of a tissue sample from the surgical specimen 
of the primary tumor. In order to compare the molecular pattern of these samples at 
poor prognosis with those at good, we selected a subgroup of cases at good 
prognosis according to the developed prognostic model. The collected material has 
been subjected to targeted NGS analysis for somatic mutation (SM), copy number 
variation (CNV) and transcriptomic analysis. In addition, quantitative-PCR, 
immunohistochemistry (IHC) and the fluorescent in situ hybridization (FISH) for 
the validation of gene alterations of interest were performed. Finally, stromal tumor 
infiltrating lymphocytes (sTIL) were also evaluated. Fisher’s exact test corrected 
for multiple comparisons was used as appropriate. In addition, Peto odds ratios 
(OR) for estimating the risk of association of a given biomarker with each 
prognostic class was determined.  
DNA extraction and qualification.  
DNA was obtained from tumour and non-neoplastic tissue matched included in 
FFPE blocks. In particular, tumour DNA from FFPE was prepared after enrichment 
for neoplastic cellularity to at least 70% using manual microdissection of 10 
consecutive 4-μm FFPE sections. Sections were then purified using the QIAamp 
DNA FFPE Tissue Kit (Qiagen) and qualified as reported elsewhere [23]. 
Mutational, CNV and transcriptomic analyses by targeted NGS.  
Matched tumour/normal DNA and RNA from all FFPE samples was subjected to 
NGS. To analyse DNA, an Ion Ampliseq custom panel was used to investigated SM 
and CNV status of all exons of 26 selected genes upon the results of published WGS 
and exome data [4, 24]: AKT1, ARID1A, ATM, BRCA1, BRCA2, CCND1, CDH1, 
CDK4, CDKN2A, ERBB2, ESR1, FGFR1, FOXA1, GATA3, MAP3K1, MTOR, 
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MYC, PALB2, PDGFRA, PDL1, PGR, PIK3CA, PTEN, RB1, TBX3, and TP53. 
Twenty nanograms of DNA were used for custom panel multiplex PCR 
amplification. The quality of the obtained libraries was evaluated by the Agilent 
2100 Bioanalyzer on-chip electrophoresis (Agilent Technologies). Emulsion PCR 
to construct the libraries of clonal sequences was performed with the Ion 
OneTouch™ OT2 System (Life Technologies). Sequencing was run on the Ion 
Proton (PI, Life Technologies) loaded with Ion PI Chip v2. Data analysis, including 
alignment to the hg19 human reference genome and variant calling, was done using 
the Torrent Suite Software v.5.0 (Life Technologies). Filtered variants were 
annotated using a custom pipeline based on vcflib (https://github.com/ekg/vcflib), 
SnpSift [25], the Variant Effect Predictor (VEP) software [26] and NCBI RefSeq 
database. Additionally, alignments were visually verified with the Integrative 
Genomics Viewer (IGV) v2.3 [27] to further confirm the presence of mutations 
identified by exome and targeted sequencing. The CNV was evaluated compared 
BAM files of single tumor sample to three normal BAM files using OncoCNV 6.8 
version software [28]. The mutational load was detected by dividing the number of 
non-synonymous mutations for the number of coding bases (mega bases) analyzed 
by sequencing. Mutational load and chromosome integrity number (CIN) were also 
evaluated [29]. The CIN was evaluated for each sample dividing length of altered 
chromosomes to length of chromosome regions investigated. Three CIN categories 
was identified: under 0.2; equal 0.2; major 0.2.  
Copy Number Variation validation by Quantitative-PCR (q-PCR).  
The q-PCR analysis of copy numbers was applied to all cases for followed genes: 
ARID1A, CDK4, ESR1, MTOR, PDL1 and PTEN. The target and reference assays 
were purchased from Applied Biosystems. RNaseP was used as endogenous control 
for normalization of analyzed locus. The following assays were used: ARID1A 
(Hs06542243), CDK4 (Hs02225231), ESR1 (Hs04321628), MTOR (Hs00873941), 
PDL1 (Hs03707126), PTEN (Hs05217581) and RNaseP (part number 4403326). 
The experimental procedure recommended by the manufacturer (Applied 
Biosystems) was followed. Twenty nanogram genomic DNA was used in the Q-
PCR reaction, and a negative control was analyzed in parallel. All q-PCR reactions 
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were run in quadruplicate in a 7900HT machine (Applied Biosystems) using 
standard cycling conditions of 10 min at 95°C, followed by 40 cycles of [95°C for 
15 sec and at 60°C for 1 min]. Pooled normal FFPE DNA was used as calibrator 
and as normal. 
Variant calling criteria for mutations and CNVs.   
Tumor mutations identified by Variant Caller Software v.5.0 (Thermo Fisher) has 
screened as follow: i) filtering-out of germline mutations identified in matched 
normal sample sequenced; ii) filtering-in mutations with at least 20 reads with 
alteration and with frequency major of 10%; iii) filtering-out artefacts through 
manual visualization of mutation using Integrative Genomics Viewer (IGV) v2.3. 
CNV detection was performed using OncoCNV 6.8 version software and followed 
criteria: i) a p-value under 0.05; ii) a q-value under 0.05. In presence of not suitable 
values, an orthogonal cross-validation using q-PCR was performed. In this case, 
only concordant results between methodical were reported. 
mRNA profiling.  
Available RNA was converted in cDNA and subsequently subjected to analysis 
using Ion Ampliseq Transcriptome Human Gene Expression Kit [30]. The matrix 
of raw counts (from Ion Torrent) was used for differential expression analysis with 
DESeq2 Bioconductor package [30]. DESeq2 was used in combination with 
RUVSeq for normalization purposes [31]. A batch factor of variation was calculated 
from the expression of empirical control genes, that is least significantly DE genes 
based on a preliminary DE analysis performed with edgeR, and such factor was 
then added to the DESeq2 design formula [32]. Here we used 5000 least significant 
DE genes and we retained K=3 factors of variation. The package ComplexHeatmap 
was used to draw the heatmaps [33]. 
Immunohistochemistry, FISH and sTIL assessment.  
Immunohistochemistry for PD1, PD-L1, phmTOR, CDK4 and CDK6 was 
performed on surgical specimens using 4 µm FFPE tissue. Fluorescent in situ 
hybridization for PD-L1, CDK4, ESR1 and mTOR was performed as well. The 
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following primary antibodies for the assessment were adopted: PD1 clone NAT, 
Rabbit monoclonal, ABCAM, dilution 1:100; PD-L1 clone E1L3Nok, Rabbit 
monoclonal, Cell Signaling, dilution 1:100; phmTOR, Rabbit polyclonal, Cell 
Signaling, dilution 1:100; CDK6, ABCAM, anti-Cdk6 antibody (EPR4515), 
ab124821, diluition 1: 200; CDK4, A304-225A-M, Betyl Laboratories, dilution 
1:400. Expression was graded based on the intensity and the percentage of stained 
cells (0= no staining, 1 = weak, 2 = moderate, 3=strong). The following primary 
chromosomal probes for the cytogenetic assessment were adopted: locus 1p36 (ph-
mTOR locus 9p13-link 9p24.1 (PD-L1); locus 12q14 (CDK4) and locus 6q25.1 
(ESR1). For each case 100 non-overlapping nuclei were counted. On 100 nuclei, 
the number of signals per nucleus is calculated as the average of these values. On 
the basis of the average of the signals’ numbers, wild-type cases were distinguished 
from cases with aberration in the copies’ number of the gene (gains as >15% of at 
least three fluorescent spots or deletions as presence of single fluorescent signals 
in >40% of nuclei after correction with non-neoplastic nuclei to avoid artefactual 
nuclear truncation). Stromal TIL were assessed on hematoxylin and eosin (H&E)-
stained sections according to the International TILs Working Group 2014 
recommendations  [34].  
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RESULTS 
1. Prognostic role of Ki67 for early-stage ILC and comparison of the optimal 
Ki67 cut-off for ILC with the optimal cut-off for IDC. 
Patients.  
Data from 457 (TS) and 222 (VS) ILC patients and 418 with IDC undergone surgery 
were gathered (overall 1097 patients; patients features for TS and the IDC cohort 
are reported in Table 1). Median age at diagnosis was 61 years (years) [range 35-96 
years] for ILC (TS) and 59 years (28-94 years) for IDC. In the TS ILC cohort, one 
hundred-twenty-two (26.7%) recurrences occurred at a median follow-up of 75 
months (range 1-396 months). Median DFS was 175 months (95% CI 153-196), 
with a 5- and 10-year rate of 82.5% and 71.4%, respectively. Median OS was 213 
months (95% CI 190-236), with a 5- and 10-year rate of 91.8% and 81.7%, 
respectively. In the IDC cohort, fifty-seven (13.6%) recurrences occurred at a 
median follow up of 75 months (range 1-122 months). Median DFS was not 
reached, with a 5- and 10-year rate of 90.4% and 68.5%, respectively. Median OS 
was not reached, with a 5- and 10-year rate of 95.8% and 81.6%, respectively. 
Table 1. Clinical-pathological and therapeutic characteristics in patients with 
invasive lobular carcinoma (training set) and invasive ductal carcinoma. 
Clinical-pathological characteristics Subcategories 
ILC [TS] 
Patients N (%) 
IDC 
Patients N (%)
Menopausal status Premenopausal 
Postmenopausal 
133 (29.3) 
322 (70.7) 
143 (34.2) 
275 (65.8) 
Performance status 
(ECOG) 
0 
1 
2 
Unknown 
265 (58.0) 
19 (4.2)  
2 (0.4) 
171 (37.4)  
371 (88.8) 
24 (5.7) 
2 (0.5) 
21 (5.0) 
Grading 1 
2 
3 
Unknown 
116 (25.4) 
151 (33.0) 
62 (13.6) 
128 (28.0) 
55 (13.2) 
223 (53.3) 
137 (32.8) 
3 (0.7) 
Oestrogen Receptor status Positive 
Negative 
Unknown 
426 (93.2) 
17 (3.7) 
14 (3.1) 
343 (82.1) 
74 (17.7) 
1 (0.2) 
Progesterone Receptor status Positive 
Negative 
Unknown 
381 (83.4) 
 49 (10.7) 
27 (6.0) 
321 (76.8) 
92 (22.0) 
5 (1.2) 
HER2 status Positive 
Negative 
Unknown 
28 (6.1) 
324 (70.9) 
105 (23.0) 
80 (19.1) 
324 (77.5) 
14 (3.4) 
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T descriptor according to TNM [7° Edition] 
1 
2 
3 
4 
Unknown 
257 (56.2) 
136 (29.8) 
37 (8.1) 
22 (4.8) 
5 (1.1) 
278 (66.5) 
129 (30.9) 
1 (0.2) 
5 (1.2) 
5 (1.2) 
Lymph-nodal status at diagnosis Positive 
Negative 
Unknown 
168 (36.8) 
275 (60.2) 
14 (3.0) 
121 (28.9) 
268 (64.2) 
29 (6.9) 
Vascular Invasion Present 
Absent  
Unknown 
80 (17.5) 
263 (57.5) 
114 (24.9) 
165 (39.5) 
238 (56.9) 
15 (3.6) 
Multifocality Present 
Absent  
Unknown 
82 (17.9) 
352 (77.0) 
23 (5.0) 
81 (19.4) 
336 (80.4) 
1 (0.2)  
Type of surgery Tumorectomy 
Quadrantectomy 
Mastectomy 
119 (26.1) 
161 (35.2) 
177 (38.7)   
265 (63.4) 
68 (16.3) 
85 (20.3) 
Lymph-node dissection Yes 
No 
Unknown 
294 (64.3) 
160(35.0) 
3 (0.7)  
203 (48.6) 
215 (51.4) 
0 (0) 
Adjuvant hormonal therapy Yes 
No 
404 (88.4) 
53 (11.6) 
327 (78.2) 
91 (21.8) 
Adjuvant chemotherapy Yes 
No 
184 (40.3) 
273 (59.7) 
197 (47.1) 
221 (52.9) 
Adjuvant Trastuzumab Yes 
No 
11 (2.4) 
446 (97.6) 
61 (14.6) 
357 (85.4) 
Adjuvant radiotherapy Yes 
No 
Unknown 
284 (62.1) 
164 (35.9) 
9 (1.9) 
289 (69.1) 
129 (30.9) 
0 (0) 
Legend Table 1. ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; 
TS, training set; N, number; ECOG, Eastern Cooperative Oncology Group. 
Ki67 distribution and maximally selected Log-Rank statistics analysis.  
As shown in Figure 1 (Panel A), tumor proliferation was significantly affected by 
histology: a statistically significant lower distribution of Ki67 immunostaining was 
found in ILC compared to IDC patients (p<0.0001). In the ILC cohort (TS), the 
optimal cut-off (absolute peak) of Ki67 identified by the maximally selected Log-
Rank statistics Analysis was 4% for DFS (Figure 1, Panel B). Patients’ 
characteristics and their differences according to group identified by the cut-off are 
reported in Table 2. In the IDC cohort, the optimal cut-off of Ki67 was 14%.  
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Figure 1. Whiskers-box plot of Ki67 values (Panel A) in patients with invasive 
lobular carcinoma and invasive ductal carcinoma; Maximally selected Log-rank 
statistics analysis (Panel B) of disease-free survival according to Ki67 (%) in the 
invasive lobular carcinoma cohort (training set). p-value, log-rank analysis. 
 
Table 2. Patients’ characteristics according to Ki67 groups in patients with invasive 
lobular carcinoma (training set). 
Clinical-pathological characteristics Subcategories 
Ki67 ≤4% 
[N=123] 
(%) 
Ki67 >4% 
[N=296] 
(%) 
p-value 
Grading 1 
2 
3 
Unknown 
50 (40.7) 
34 (27.6) 
8 (6.5) 
31 (25.2) 
65 (22.0) 
113 (38.2) 
52 (17.6) 
66 (22.2) 
<0.0001 
Oestrogen Receptor status Positive 
Negative 
Unknown 
116 (94.3) 
7 (5.7) 
0 (0) 
285 (96.3) 
9 (3.0) 
2 (0.7) 
0.29 
Progesterone Receptor status Positive 
Negative 
Unknown 
100 (81.3) 
 18 (14.6) 
5 (4.1) 
259 (87.5) 
30 (10.1) 
7 (2.4) 
0.25 
HER2 status Positive 
Negative 
Unknown 
8 (6.5) 
91 (74.0) 
24 (19.5) 
20 (6.8) 
228 (77.0) 
48 (16.2) 
0.72 
T descriptor according to TNM [7° 
Edition] 
1 
2 
3 
4 
Unknown 
81 (65.9) 
31 (25.2) 
9 (7.3) 
1 (0.8) 
1 (0.8) 
159 (53.7) 
92 (31.1) 
27 (9.1) 
18 (6.1) 
0 (0) 
0.02 
Lymph-nodal status  Positive 
Negative 
Unknown 
34 (27.6) 
87 70.7) 
2 (1.7) 
121 (40.9) 
165 (55.7) 
10 (3.4) 
0.02 
Vascular Invasion Present 
Absent  
Unknown 
16 (13.0) 
82 (66.7) 
25 (20.3) 
62 (20.9) 
178 (60.1) 
56 (19.0) 
0.16 
Multifocality Present 
Absent  
Unknown 
26 (21.1) 
94 (76.4) 
3 (2.4) 
53 (17.9) 
231 (78.0) 
12 (4.1)  
0.56 
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Type of surgery Tumorectomy 
Quadrantectomy 
Mastectomy 
39 (31.7) 
46 (37.4) 
38 (30.9)   
76 (25.7) 
103 (34.8) 
117 (39.5) 
0.31 
Lymph-node dissection Yes 
No 
Unknown 
72 (58.5) 
51 (41.5) 
0 (0.0)  
111 (37.5) 
184 (62.2) 
1 (0.3) 
0.62 
Adjuvant hormonal therapy Yes 
No 
109 (88.6) 
14 (11.4) 
276 (93.2) 
20 (6.8) 
0.11 
Adjuvant chemotherapy Yes 
No 
43 (35.0) 
80 (65.0) 
129 (43.6) 
167 (56.4) 
0.1 
Adjuvant radiotherapy Yes 
No 
Unknown 
85 (69.1) 
34 (27.6) 
4 (3.3) 
106 (35.8) 
185 (62.5) 
5 (1.7) 
0.19 
Legend Table 2. N, number; p-value, chi-square test. 
Multivariate Analysis and Internal Validation Analysis.  
At the multivariate analysis for ILC patients, performance status and nodal status 
were independent predictors for DFS; performance status, nodal status, Ki67 and 
T-size were independent predictors of OS. At the internal cross-validation analysis, 
all factors were confirmed as independent factors for both DFS and OS (Table 3).  
Table 3. Multivariate analysis in patients with invasive lobular carcinoma (training 
set). 
ILC Predictors 
DFS 
HR (95% CI) 
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
OS 
HR (95% CI) 
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
Performance Status (ECOG) 
[1-2 vs 0] 
3.73 (1.50-9.30) 
[0.005] 
100% 
3.27 (1.49-7.18) 
[0.003] 
96% 
Nodal Status [Positive vs 
Negative] 
3.75 (1.70-8.26) 
[0.001] 
100% 
2.96 (1.53-5.74) 
[0.001] 
100% 
Ki67 
(>4% vs ≤4%) 
- 
- 
2.28 (1.0-5.19) 
[0.05] 
94% 
T descriptor according to 
TNM [7° Edition] 
(3-4 vs 1-2) 
- 
- 
2.6 (1.31-5.13) 
[0.006] 
96% 
Legend Table 3. ILC, invasive lobular carcinoma; DFS, disease-free survival; HR, 
Hazard Ratio; CI: confidence intervals; OS, overall survival, vs, versus; ECOG, 
Eastern Cooperative Oncology Group. 
With regard to IDC patients, performance status, age at diagnosis, vascular invasion 
and grading were independent predictors of DFS; performance status, age at 
diagnosis, vascular invasion, T-size and hormonal receptor status were independent 
predictors of OS, with a high replication rate at the internal validation analysis 
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(Table 4).  
Table 4. Multivariate analysis in patients with invasive ductal carcinoma. 
IDC Predictors 
DFS 
HR (95% CI) 
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
OS 
HR (95% CI) 
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
Performance Status 
(ECOG) 
[1-2 vs 0] 
3.39 (1.49-7.71) 
[0.004] 
95% 
5.64 (1.95-16.32) 
[0.001] 
90% 
Age at diagnosis   
[>60 vs ≤60] 
2.40 (1.17-4.95) 
[0.017] 
85% 
8.68 (1.90-39.75) 
[0.005] 
95% 
Vascular Invasion 
[Present vs Absent] 
2.01 (1.04-3.86) 
[0.037] 
80% 
2.37 (0.90-6.25) 
[0.08] 
75% 
Grading  
[3 vs 1-2] 
3.60 (1.86-6.97) 
[<0.0001] 
90% - - 
T descriptor according to 
TNM [7° Edition] 
(3-4 vs 1-2) 
- - 
6.29 (1.39-28.35) 
[0.0.17] 
90% 
Hormonal receptor Status 
[Neg. Vs Pos.] 
- - 
8.07 (3.09-21.05) 
[<0.001] 
90% 
Legend Table 4. IDC, invasive ductal breast carcinoma; DFS, disease-free survival; 
HR, Hazard Ratio; CI: confidence intervals; OS, overall survival, vs, versus; 
ECOG, Eastern Cooperative Oncology Group; N, negative; Pos., positive. 
Survival Analysis according to Ki67 cut-off.  
In ILC patients, the optimal Ki67 cut-off was an independent predictor for OS, and 
it significantly discriminated the DFS. Survival curves according to Ki67 for ILC 
patients are shown in Figure 2, Panels A-B. In IDC patients, the optimal Ki67 cut-
off was not independent at multivariate analysis; besides, Ki67 significantly 
discriminated the prognosis at unadjusted Kaplan-Meier curves (Figure 2, Panels 
C-D).  
Figure 2. Disease-free survival (Panel A and C) and overall survival (Panel B and 
D) according to Ki67 in the invasive lobular carcinoma cohort (Panel A and B) and 
in the ductal invasive carcinoma cohort (Panel C and D). p-value, log-rank analysis; 
DFS, disease-free survival; OS, overall survival.  
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STEPP Analysis.  
The STEPP analysis of Ki67 assay in terms of DFS rates at 60 months according to 
histology was reported in Figure 3. This analysis showed that in the presence of low 
values of Ki67, patients with IDC have a better DFS than patients with ILC, while 
with the increase of Ki67 value the prognosis tends to overlap. 
Figure 3. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 
assay according to histology: DFS rates at 60 months of patients with invasive 
lobular and ductal carcinoma according to patients’ subpopulations clustered by 
Ki67 (%). DFS, disease-free survival; ILC, invasive lobular carcinoma; IDC, 
invasive ductal carcinoma.  
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External Validation Analysis.  
The VS consisted of 222 patients with operable or locally advanced ILC patients 
(Table 5). Median age was 59 years (range 33-88 years) and median follow-up was 
71 months (range 1-195 months). The optimal Ki67 cut-off for OS, independent 
predictor at the multivariate analysis in the TS, was 5%. The found Ki67 cut-off 
significantly discriminated the prognosis in the VS (Figure 4).  
Table 5. Clinical-pathological and therapeutic characteristics in patients with 
invasive lobular carcinoma (validation set). 
Characteristics Subcategories 
ILC [VS] 
Patients N (%) 
Grading 1 
2 
3 
Unknown 
2 (0.9) 
180 (81.1) 
15 (6.8) 
25 (11.3) 
Oestrogen Receptor status Positive 
Negative 
Unknown 
184 (82.9) 
38 (17.1) 
0 (0.0) 
Progesterone Receptor status Positive 
Negative 
Unknown 
161 (72.5) 
61 (27.5) 
0 (0.0) 
HER2 status Positive 
Negative 
Unknown 
11 (5.0) 
184 (82.9) 
27 (12.2) 
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T descriptor according to TNM [7° Edition]  1 
2 
3 
4 
Unknown 
113 (50.9) 
81 (36.5) 
15 (6.8) 
7 (3.2) 
6 (2.7) 
Lymph-nodal status  Positive 
Negative 
Unknown 
92 (41.4) 
119 (53.6) 
11 (5.0) 
Adjuvant chemotherapy Yes 
No 
197 (47.1) 
221 (52.9) 
Legend Table 5. ILC, invasive lobular breast carcinoma; VS, validation set; N, 
number. 
Figure 4. Overall survival according to Ki67 in the validation set of invasive lobular 
carcinoma. p-value, log-rank analysis; OS, overall survival. 
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2. Investigation of the impact on survival of adjuvant chemotherapy in the 
lobular histotype. 
Patients. 
Data from 473 patients with luminal/HER2-negative pure ILC were gathered (Table 
6). Median age was 58 years [range 26-96]. At a median follow-up of 77 months 
[range 1-225], 403 pts (85.2%) were alive and 70 pts (14.8%) experienced 
locoregional or distant recurrence. The 5- and 10-yrs DFS rate were 84.6% and 
72.9%, respectively. The 5- and 10-yrs rate OS were 92.1% and 80.7%, respectively. 
The 5- and 10-yrs rate DDFS were 88.5% and 77.9%, respectively. 
Table 6. Clinical-pathological and therapeutic characteristics. 
Characteristics Subcategories Patients N (%) 
T descriptor according to 
TNM [7° Edition] 
1 
2 
3 
4 
Unknown 
268 (56.7) 
143 (30.2) 
35 (7.4) 
16 (3.4) 
11 (2.3) 
Lymph-nodal status  0 
1 
2 
3 
Unknown 
282 (59.6) 
106 (22.4) 
40 (8.5) 
32 (6.8) 
13 (2.7) 
Ki67 ≤4% 
>4% 
Unknown 
100 (21.1) 
334 (70.6) 
39 (8.2) 
Grading 1 
2 
3 
Unknown 
108 (22.8) 
167 (35.3) 
94 (19.9) 
104 (22.0) 
Type of Surgery Tumorectomy 
Quadrantectomy 
Mastectomy 
126 (26.6) 
187 (39.5) 
160 (33.8) 
Adjuvant hormonal therapy Yes 
No 
Unknown 
415 (87.7) 
29 (6.1) 
29 (6.1) 
Adjuvant chemotherapy Yes 
No 
Unknown 
209 (44.2) 
235 (49.7) 
29 (6.1) 
Adjuvant radiotherapy Yes 
No 
Unknown 
244 (51.6) 
191 (40.4) 
38 (8.0) 
 
Legend Table 6. N, number. 
Multivariate Analysis. 
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Tumour-category according to TNM, lymph-node status and age at diagnosis were 
independent predictors for DFS at multivariate analysis. Nodal status and age were 
independent predictors for OS (Table 7). 
Table 7. Independent predictors of outcome at multivariate analysis.  
Predictors 
DFS 
HR (95% CI) 
[p-value] 
OS 
HR (95% CI) 
[p-value] 
Age at diagnosis  
[>57 vs ≤57] 
1.60 (0.96-2.67) 
[p=0.072] 
2.71 (1.39-5.31) 
[p=0.003] 
Nodal Status 
(Pos. vs Neg.) 
2.62 (1.54-4.49) 
[p<0.0001] 
4.46 (2.87-8.71) 
[<0.0001] 
T-category according to TNM  
(2-4 vs 1) 
1.31 (0.99-1.72) 
[p=0.061] 
- 
 
Legend Table 7. DFS, disease-free survival; HR, Hazard Ratio; CI: confidence 
intervals; OS, overall survival. vs, versus; Neg., negative; Pos., positive. 
Propensity score analysis. 
After adjusting for independent factors with the propensity score method (178 
patients evaluable), no significant effect of adjuvant chemotherapy upon DFS and 
DDFS was found (Figure 5, Panels A-B), whereas a significant prognostic effect of 
the addition of adjuvant chemotherapy to adjuvant hormonotherapy upon OS was 
found (Figure 5, Panel C).  
Figure 5. Disease-free survival (Panel A), distant disease-free survival (Panel B) 
and overall survival (Panel C) according to adjuvant chemotherapy. p-value, log-
rank analysis; DFS, disease-free survival; DDFS, distant disease-free survival; OS, 
overall survival; aCT, adjuvant chemotherapy. 
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According to prognostic factors, adjuvant chemotherapy significantly prolongs 
DFS, DDFS and OS in patients with Tumor-category >1 and node-positive status 
(Figure 6). Moreover, adjuvant chemotherapy significantly prolongs OS in patients 
with Ki67>4% (p=0.0009) and Grading 2-3 (p=0.01). 
Figure 6. Disease-free survival, distant disease-free survival and overall survival 
according to adjuvant chemotherapy in patients with Tumor-category <1 (Panels A-
C) and in patients with node-positive status (Panels D-F). p-value, log-rank 
analysis; DFS, disease-free survival; DDFS, distant disease-free survival; OS, 
overall survival; aCT, adjuvant chemotherapy. 
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3. Building and validation of a prognostic nomogram for early-stage ILC 
patients in order to identify those prognostic ‘outliers’ candidate to undergo to 
genomic analysis. 
Patients.  
Data from overall 773 patients (491 patients for TS and 282 for VS) with ILC who 
underwent surgery were gathered. Patients’ characteristics of the TS are listed in 
Table 8. At a median follow-up of 77 months (range 1-396), median DFS was 175 
months (95% CI 153-197), with a 5-/10-year rate of 82.4%/70.5%, respectively. 
Median OS was 213 months (95% CI 190-236), with a 5-/10-year rate of 
91.8%/82.2%, respectively. 
Table 8. Clinico-pathological and therapeutic characteristics in patients with 
invasive lobular carcinoma (Training Set, N=491). 
Characteristics Subcategories 
ILC [TS] 
Patients N (%) 
Menopausal status Premenopausal 
Postmenopausal 
142 (28.9) 
349 (71.1) 
Grading 1 
2 
3 
Unknown 
124 (25.3) 
155 (31.6) 
75 (15.3) 
137 (27.9) 
Oestrogen Receptor status Positive 
Negative 
Unknown 
460 (93.7) 
17 (3.5) 
14 (2.8) 
Progesterone Receptor 
status 
Positive 
Negative 
Unknown 
412 (83.9) 
 52 (10.6) 
27 (5.5) 
Ki67 <5% 
≥5% 
Unknown 
136 (27.7) 
313 (63.7) 
42 (8.6) 
HER2 status Positive 
Negative 
Unknown 
27 (5.5) 
353 (71.9) 
111 (22.6) 
T category 
according to TNM [7° 
Edition] 
1 
2 
3 
4 
Unknown 
276 (56.2) 
148 (30.1) 
40 (8.1) 
23 (4.7) 
4 (0.9) 
Lymph-nodal status Positive 
Negative 
Unknown 
180 (36.7) 
297 (60.5) 
14 (2.8) 
Vascular Invasion Present 
Absent  
Unknown 
87 (17.7) 
290 (59.1) 
114 (23.2) 
Multifocality Present 
Absent  
Unknown 
93 (18.9) 
375 (76.4) 
23 (4.7) 
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Type of surgery Tumorectomy 
Quadrantectomy 
Mastectomy 
130 (26.5) 
165 (33.6) 
196 (39.9)   
Adjuvant hormonal therapy Yes 
No 
Unknown 
432 (88.0) 
534(11.0) 
5 (1.0) 
Adjuvant chemotherapy Yes 
No 
199 (40.5) 
292 (59.5) 
Adjuvant Trastuzumab Yes 
No 
11 (2.2) 
480 (97.8) 
Adjuvant radiotherapy Yes 
No 
Unknown 
301 (61.3) 
177 (36.0) 
13 (2.6) 
Legend-Table 8. ILC, invasive lobular carcinoma; TS, training set; N, number. 
Multivariate analysis.  
At the multivariate analysis, T-category (1-2) and negative nodal status were 
independent predictors for longer DFS; age at diagnosis <60 years, negative nodal 
status and Ki67 <5% were independent predictors for longer OS. At the internal 
cross-validation analysis, all variables were confirmed as independent factors 
(Table 9). 
Table 9. Multivariate analysis in patients with invasive lobular carcinoma (Training 
Set, N=491). 
Predictors 
DFS 
HR (95% CI)  
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
OS 
HR (95% CI)  
[p-value] 
Replication 
Rate 
[Internal 
Validation] 
T-category according to 
TNM (7° Edition) 
[3-4 vs. 1-2] 
1.78 (0.97-3.25)  
[0.062] 
60% - - 
Nodal Status   
[Positive vs. Negative] 
2.46 (1.50-4.05) 
[<0.0001] 
95% 
3.32 (1.71-6.45) 
[<0.0001] 
100% 
Age  
[>60 years vs. ≤60 years] 
- - 
2.19 (1.14-4.21) 
[0.019] 
90% 
Ki67 
[≥5% vs. <5%] 
- - 
2.47 (1.02-5.94) 
[0.044] 
80% 
Prognostic score assessment.  
According to the HR obtained at the multivariate analysis, a prognostic scoring 
index was assigned to each patient to identify the individual risk of recurrence and 
death (Table 10). Based on the outcome, patients were divided into three risk classes 
for DFS and OS: low/intermediate/high risk of recurrence or death: 
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score<2/score=2/score>2. According to the prognostic model, a significant 
prognostic difference between patients at low, intermediate, and high risk was 
found for DFS (10-year: 76.3%, 67.6%, and 39.8%, p<0.0001; area under the curve 
[AUC] 0.60 (Standard Error [SE], 0.03)); Figure 7, Panel A) and OS (10-year: 
92.7%, 82.7% and 67.1%, p<0.0001; AUC 0.66 (SE, 0.03)).  
Table 10. Prognostic score assessment, according to outcome. 
 Score points 
DFS 0 1 2 
T-category (according to TNM 7° Edition) 1-2 3-4 - 
Nodal status Negative - Positive 
OS  
Nodal status Negative - Positive 
Age at diagnosis ≤60 years >60 years - 
Ki67 <5% ≥5% - 
Legend Table 10. DFS, disease-free survival; OS, overall survival. 
External validation analysis.  
The VS consisted of 282 patients (Table 11); median follow-up 86 months (range 
1-348). The model, developed in the TS, has been proven to be equally able to 
discriminate the DFS in the VS (Figure 7, Panel B). Indeed, a significant prognostic 
difference between patients at low, intermediate, and high risk was found (10-year: 
81.5%, 53.4%, 44.0%, p<0.0001; AUC 0.70 (SE, 0.03)). Considering the overall 
population (TS plus VS), the performance of the model adjusting for the set was 
confirmed (p<0.001), without difference in terms of DFS between the TS and VS 
(HR, 1.02 (95%CI 0.77-1.37, p=0.88). 
Table 11. Clinical-pathological and therapeutic characteristics in patients with 
invasive lobular carcinoma (Validation Set, N=282).  
Characteristics Subcategories 
ILC [VS] 
Patients N (%)
Grading 1 
2 
3 
Unknown 
6 (2.1) 
74 (26.2) 
79 (28.0) 
123 (43.6) 
Oestrogen Receptor status Positive 
Negative 
234 (83.0) 
12 (4.3) 
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Unknown 36 (12.8) 
Progesterone Receptor 
status 
Positive 
Negative 
Unknown 
215 (76.2) 
30 (10.6) 
37 (13.1) 
Ki67 <5% 
≥5% 
Unknown 
8 (2.8) 
158 (56.0) 
116 (41.1) 
HER2 status Positive 
Negative 
Unknown 
18 (6.4) 
174 (61.7) 
90 (31.9) 
T category 
according to TNM  
[7° Edition] 
1 
2 
3 
4 
Unknown 
127 (45.0) 
94 (33.3) 
15 (5.3) 
9 (3.2) 
37 (13.1) 
Lymph-nodal status Positive 
Negative 
Unknown 
127 (45.0) 
140 (49.6) 
15 (5.4) 
Type of surgery Tumorectomy 
Quadrantectomy 
Mastectomy 
34 (12.1) 
135 (47.9) 
113 (40.1) 
Adjuvant hormonal 
therapy 
Yes 
No 
212 (75.2) 
70 (24.8) 
Adjuvant chemotherapy Yes 
No 
200 (70.9) 
82 (29.1) 
Adjuvant Trastuzumab Yes 
No 
13 (4.6) 
269 (95.4) 
Legend Table 11. ILC, invasive lobular carcinoma; VS, validation set; N, number.  
Figure 7. Disease-free survival (DFS) according to the risk-class model in the 
Training set [Panel A] and in the Validation set [Panel B]. p-value: log-rank 
analysis. 
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Patients’ Sample.  
The tissue sample from the surgical specimen of the primary tumor matched with 
the clinico-pathological annotations, required by the inclusion criteria to be 
addressed to NGS analysis, was available at the coordinating center for 20 and 14 
patients scored at poor and good prognosis class according to the DFS model, 
respectively (Table 12, Figure 8). 
Table 12. Clinico-pathological and therapeutic characteristics in the 34 patients 
undergone molecular analysis according to prognosis. 
Characteristics Subcategories 
Poor Group 
Patients N (%) 
Good Group 
Patients N (%) 
Grading 1 
2 
3 
6 (30.0) 
10 (50.0) 
4 (20.0) 
3 (21.4) 
9 (64.4) 
2 (14.2) 
Oestrogen Receptor status Positive 
Negative 
Unknown 
17 (85.0) 
1 (5.0) 
2 (10.0) 
12 (85.8) 
1 (7.1) 
1 (7.1) 
Progesterone Receptor status Positive 
Negative 
Unknown 
13 (65.0) 
3 (15.0) 
4(20.0) 
11 (78.6) 
0 (0) 
3 (21.4) 
Ki67 <5% 
≥5% 
Unknown 
2 (10.0) 
17 (85.0) 
1 (5.0) 
8 (57.2) 
5 (35.7) 
1 (7.1) 
HER2 status Positive 
Negative 
Unknown 
2 (10.0) 
17 (85.0) 
1 (5.0) 
1 (7.1) 
5 (35.7) 
8 (57.2) 
T category according to TNM [7° Edition] 1 
2 
3 
4 
3 (15.0) 
15 (75.0) 
1 (5.0) 
1 (5.0) 
8 (57.1) 
5 (35.7) 
1 (7.1) 
0 (0) 
Lymph-nodal status Positive 
Negative 
Unknown 
16 (80.0) 
3 (15.0) 
1 (5.0) 
3 (21.4) 
11 (78.6) 
0 (0) 
Vascular Invasion Present 
Absent  
Unknown 
16 (80.0) 
3 (15.0) 
1 (5.0) 
3 (21.4) 
11 (78.6) 
0 (0) 
Adjuvant hormonal therapy Yes 
No 
17 (85.0) 
3(15.0) 
10 (71.4) 
4 (28.6) 
Adjuvant chemotherapy Yes 
No 
11 (55.0) 
9 (45.0) 
8 (57.2) 
6 (42.8) 
Adjuvant radiotherapy Yes 
No 
12 (60.0) 
8 (40.0) 
9 (64.3) 
5 (35.7) 
Legend-Table 12. N, number.  
Figure 8. Disease-free survival (DFS) in patients at poor and good prognosis 
selected for molecular analysis. p-value: log-rank analysis. 
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Molecular features according to prognosis.  
Mutations were observed in 29 cases of all series for 26 genes analysed. In detail: 
one mutation was observed in 10/34 cases (29.4%), more than one in 19/34 (55.9%) 
cases while no alteration in 5/34 cases (14.7%). A mean of 12.4 mutations/Mb was 
achieved. The most commonly mutated gene in the whole cohort was CDH1 
(38.2%), followed by PIK3CA (29.4%) and TP53 (20.6%) (Figure 9 (Panel A), 
Table 13). Copy number variation was observed in all cases: one CNV was 
observed in 5/34 cases (14.7%), while more than one in 29/34 cases (85.3%). Loss 
of heterozygosis of CDH1 (44.1%) and ARID1A (38.2%) were the most frequent 
CNV events, followed by gain in FGFR1 and ESR1 (each 12/34; 35.3%).  The 
prevalence of gene somatic mutation (SM) and CNV according to prognostic 
groups was reported in Table 13. Interestingly, gain of CDK4 was (7/34; 21.2%) 
exclusively present in this poor prognosis group, whereas no good prognosis case 
showed this alteration (p=0.03). Moreover, CDK4 gain (at NGS analysis) resulted 
in a statistically significant higher chance to be associated with poor prognosis (OR 
7.98, 95%CI 1.51-42.1, p=0.014) (Figure 9, Panel B).  
Table 13. Prevalence of somatic mutations and copy number variations analysis of 
the 26 genes in the 34 invasive lobular carcinoma patients according to prognostic 
groups. 
Gene Alteration 
Poor Group 
Patients N (%) 
Good Group 
Patients N (%) 
Total  
N (%) 
p-value* 
AKT1 - - - - - 
ARID1A Loss 5 (25.0) 8 (57.1) 13 (38.2) 0.08 
ATM SM 0 1 (7.1) 1 (2.9) - 
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BRCA1 SM 0 1 (7.1) 1 (2.9) - 
BRCA2 SM 1 (5.0) 1 (7.1) 2 (5.9) - 
CCND1 Gain 4 (20.0) 1 (7.1) 5 (14.7) - 
CDH1 
SM 10 (50.0) 3 (21.4) 13 (38.2) - 
Loss 11 (55.0) 4 (28.6) 15 (44.1) - 
CDK4 Gain 7 (35.0) 0 7 (20.6) 0.03 
CDKN2A 
SM 3 (15.0) 1 (7.1) 4 (11.8) - 
Loss 1 (5.0) 2 (14.3) 3 (8.8) - 
ERBB2 
SM 1 (5.0) 0 1 (2.9) - 
Gain 4 (20.0) 3 (21.4) 7 (20.6) - 
ESR1 Gain 7 (35.0) 5 (35.7) 12 (35.3) - 
FGFR1 
SM 0 1 (7.1) 1 (2.9) - 
Gain 7 (35.0) 5 (35.7) 12 (35.3) - 
FOXA1 
SM 1 (5.0) 3 (21.4) 4 (11.8) - 
Gain 1 (5.0) 1 (7.1) 2 (5.9) - 
GATA3 SM 1 (5.0) 1 (7.1) 2 (5.9) - 
MAP3K1 
SM 2 (10.0) 0 2 (5.9) - 
Gain 4 (20.0) 1 (7.1) 5 (14.7) - 
MTOR Gain 5 (25.0) 1 (7.1) 6 (17.6) - 
MYC 
SM 1 (5.0) 1 (7.1) 2 (5.9) - 
Gain 5 (25.0) 2 (14.3) 7 (20.6) - 
PALB2 SM 0 1 (7.1) 1 (2.9) - 
PDGFRA SM 1 (5.0) 1 (7.1) 2 (5.9) - 
PDL1 Gain 4 (20.0) 2 (14.3) 6 (17.6) - 
PGR - - - - - 
PIK3CA 
SM 7 (35.0) 3 (21.4) 10 (29.4) - 
Gain 6 (30.0) 2 (14.3) 8 (23.5) - 
PTEN 
SM 1 (5.0) 0 1 (2.9) - 
Loss 6 (30.0) 4 (28.6) 10 (29.4) - 
RB1 SM 1 (5.0) 2 (14.3) 3 (8.8) - 
TBX3 SM 1 (5.0) 1 (7.1) 2 (5.9) - 
TP53 
SM 1 (5.0) 5 (35.7) 7 (20.6) 0.09 
Loss 4 (20.0) 2 (14.3) 6 (17.6) - 
Legend Table 13. N, Number; SM, somatic mutation; p-value* according to 
Fisher’s exact test (only p<0.10 are reported). 
Figure 9. Comparison of mutational load, chromosome integrity number, somatic 
mutations and copy number variation between patients with poor prognosis and 
patients with good prognosis [Panel A]. Odds Ratio analysis [Panel B] of somatic 
mutations (Panel A) and copy-number variation (Panel B) according to prognosis: 
an OR<1 indicates a higher chance to be associated with good prognosis; an OR>1 
indicates a higher chance to be associated with poor prognosis. CIN, chromosome 
integrity number; CNV, copy number variation; OR, odds Ratio; CI, confidence 
interval; SM, somatic mutation; CNV, copy number variation. 
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When grouping the molecular alterations involved in the regulation of G1/S phase 
cell cycle progression herein evaluated (CDK4 and CCND1 gain or CDKN2A 
mutation), this signature was significantly more associated with poor prognosis in 
the whole patients’ sample (OR 6.24, 95%CI 1.59-24.5, p=0.009), and in the RB1 
wild type population (32 patients, OR 5.33, 95% CI 1.33-21.28, p=0.018).  
RNA was available for 20 samples (12 poor and 8 good). Ninety genes (as reported 
in Figure 10) showed an adjusted p-value under 0.05 and were able to discriminate 
all good samples to poor ones.  
Figure 10. Heatmap displaying normalized expression values of the 90 
differentially expressed genes between the two prognostic groups at a p-value cutoff 
of 0.05. Hierarchical clustering correctly separates the good and the poor samples. 
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Table 14. List of differential expressed genes ordered according to decrement of 
adjust p-value (padj). 
Gene baseMean log2FoldChange lfcSE stat pvalue padj 
FAM118A 287.9815 -4.16484 0.71739 -5.80555 6.42E-09 6.23E-05 
METTL17 11.96358 5.484037 0.95744 5.727812 1.02E-08 6.23E-05 
ACAP3 54.69334 3.508042 0.641507 5.468437 4.54E-08 0.000185 
ARMCX4 61.82765 -2.45036 0.502328 -4.878 1.07E-06 0.002949 
ATP5G2 135.398 1.830659 0.377078 4.854862 1.2E-06 0.002949 
CLMP 47.86417 -3.11953 0.65164 -4.7872 1.69E-06 0.003184 
BBS9 57.56298 -2.91145 0.61287 -4.75052 2.03E-06 0.003184 
SLC19A1 6.593031 5.736359 1.208823 4.745409 2.08E-06 0.003184 
TNFRSF25 39.16437 3.034054 0.64686 4.690436 2.73E-06 0.003708 
UNG 10.91649 3.969202 0.866673 4.579818 4.65E-06 0.005697 
GAS1 486.2476 -1.83906 0.408547 -4.50148 6.75E-06 0.006523 
LRBA 122.4088 -1.97506 0.439645 -4.49241 7.04E-06 0.006523 
CPA1 2855.778 -4.10595 0.914598 -4.48935 7.14E-06 0.006523 
GOLGA6L10 22.43287 -2.17485 0.487036 -4.46548 7.99E-06 0.006523 
AGAP5 160.3393 -2.20732 0.495351 -4.45608 8.35E-06 0.006523 
CSGALNACT2 59.80484 -2.45501 0.551499 -4.45153 8.53E-06 0.006523 
GLTP 9.947518 3.990971 0.911693 4.377538 1.2E-05 0.008643 
HJURP 20.33044 3.336638 0.766142 4.355115 1.33E-05 0.009045 
XKRY2 8.999908 -4.88396 1.132215 -4.31364 1.61E-05 0.010346 
NBPF9 455.8717 -1.8637 0.436331 -4.27129 1.94E-05 0.011895 
MRC1 52.49322 -3.11718 0.737505 -4.22665 2.37E-05 0.013687 
RNF214 79.04164 -2.61661 0.620365 -4.21786 2.47E-05 0.013687 
SPTBN2 92.77476 2.947034 0.700272 4.208416 2.57E-05 0.013687 
NBPF10 504.807 -1.72624 0.414547 -4.16416 3.12E-05 0.015939 
TAAR5 75.10982 -2.60199 0.627422 -4.14711 3.37E-05 0.016486 
C21orf33 17.91853 3.182556 0.76936 4.13663 3.52E-05 0.016593 
CACYBP 243.1032 1.782038 0.43251 4.120219 3.79E-05 0.01712 
C5orf42 165.0362 -2.90166 0.706717 -4.10583 4.03E-05 0.01712 
ANKRD10 108.9637 -1.87962 0.458939 -4.09559 4.21E-05 0.01712 
KRTAP21-2 173.7503 -2.21893 0.542046 -4.09362 4.25E-05 0.01712 
TSPY3 93.7732 -2.99832 0.734317 -4.08314 4.44E-05 0.01712 
WDR77 64.45564 2.922548 0.71669 4.077839 4.55E-05 0.01712 
OR4D5 49.46553 -2.59136 0.636026 -4.07429 4.62E-05 0.01712 
C14orf178 105.7455 -1.4312 0.351968 -4.06627 4.78E-05 0.017199 
TMEM189 51.661 2.614833 0.645649 4.049929 5.12E-05 0.017877 
DKFZP434I0714 237.9083 -1.28443 0.317623 -4.04388 5.26E-05 0.017877 
C7orf26 49.75301 2.066796 0.512317 4.034213 5.48E-05 0.017981 
ARSI 25.03895 -3.07882 0.764009 -4.02983 5.58E-05 0.017981 
ZNF141 79.1625 -1.42766 0.357591 -3.99244 6.54E-05 0.020526 
OR1I1 81.96834 -2.04006 0.511883 -3.98541 6.74E-05 0.020615 
ZMIZ1 46.35856 2.447771 0.616872 3.968037 7.25E-05 0.021636 
NPPA 27.3433 -3.99812 1.015776 -3.93602 8.28E-05 0.024145 
ZNF276 25.84982 -2.63025 0.669396 -3.92928 8.52E-05 0.024254 
NPHP3 15.22506 -2.30989 0.591356 -3.90609 9.38E-05 0.026096 
AGAP6 166.9166 -1.93087 0.497415 -3.8818 0.000104 0.027516 
TMEM14A 34.36528 2.210491 0.569804 3.879385 0.000105 0.027516 
BIRC5 12.37289 3.815822 0.984161 3.877235 0.000106 0.027516 
PNKD 40.58867 2.142505 0.555759 3.855101 0.000116 0.029395 
FAM69B 7.964359 3.49476 0.908079 3.848519 0.000119 0.029395 
SMTN 7.46489 -2.83132 0.736591 -3.84382 0.000121 0.029395 
ABCA5 108.0626 -2.1638 0.563334 -3.84107 0.000123 0.029395 
TK1 6.69306 4.122105 1.076128 3.830498 0.000128 0.029395 
ROBO1 27.95859 -2.56238 0.669015 -3.83007 0.000128 0.029395 
FHL3 90.85706 -2.0058 0.524108 -3.82708 0.00013 0.029395 
NLGN2 78.29472 -2.02182 0.52942 -3.81893 0.000134 0.029831 
S100A1 27.88531 2.562766 0.673243 3.806599 0.000141 0.030485 
RMRP 79125.52 1.860016 0.488868 3.804738 0.000142 0.030485 
THEMIS2 11.09583 3.748385 0.986994 3.797781 0.000146 0.030813 
MRP63 5.867143 3.068536 0.812317 3.77751 0.000158 0.032865 
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SLC4A7 85.35451 -2.44587 0.649903 -3.76344 0.000168 0.034192 
LOC148413 17.15092 2.726837 0.726778 3.751951 0.000175 0.034759 
ZNF608 19.34841 -3.26149 0.869471 -3.75111 0.000176 0.034759 
EPC1 23.07644 -2.37828 0.636215 -3.73818 0.000185 0.034844 
DEGS2 15.63481 3.066862 0.820782 3.736513 0.000187 0.034844 
NENF 298.75 1.252268 0.335529 3.732216 0.00019 0.034844 
GRAMD1A 12.25981 1.980602 0.530794 3.731395 0.00019 0.034844 
ARSB 34.92913 -2.50226 0.670665 -3.73101 0.000191 0.034844 
ZNF808 186.229 -1.62569 0.437399 -3.71672 0.000202 0.035845 
RAB40C 31.8133 1.902918 0.512028 3.716437 0.000202 0.035845 
CD33 50.0631 -1.46189 0.394135 -3.70911 0.000208 0.036371 
C9orf123 68.92144 2.434518 0.657075 3.705086 0.000211 0.036433 
LOC100506060 12.6985 -2.76485 0.749924 -3.68684 0.000227 0.038418 
GPRC5A 17.32872 1.883578 0.51121 3.684546 0.000229 0.038418 
SLC27A3 8.187408 2.34817 0.639174 3.673756 0.000239 0.039537 
NRSN2 12.68688 2.725802 0.744313 3.662171 0.00025 0.040817 
CDRT15P1 177.3026 -1.30105 0.356446 -3.65007 0.000262 0.042227 
RALGDS 8.410915 2.382174 0.654971 3.637069 0.000276 0.043505 
SLC39A11 31.47888 2.585836 0.711835 3.632632 0.000281 0.043505 
PAR-SN 191.3378 -1.31291 0.36144 -3.63243 0.000281 0.043505 
ZNF354B 15.38799 -2.6369 0.726935 -3.62742 0.000286 0.043802 
AMY2A 2103.127 -3.25841 0.902669 -3.60975 0.000306 0.045833 
RABGAP1 56.88308 -2.5086 0.695037 -3.6093 0.000307 0.045833 
BLID 104.6526 -1.26807 0.351802 -3.60451 0.000313 0.046125 
GOLGA6C 71.62324 -2.00299 0.556517 -3.59915 0.000319 0.046362 
ZNF543 11.90684 -2.89538 0.804947 -3.59698 0.000322 0.046362 
COG5 61.98341 -1.70582 0.475018 -3.59106 0.000329 0.046407 
AZI2 21.49553 -2.14747 0.59807 -3.59067 0.00033 0.046407 
ZNF295 11.98757 -2.20519 0.615077 -3.58523 0.000337 0.046847 
OR10H5 98.31277 -1.89321 0.528516 -3.58213 0.000341 0.046874 
POU5F1P3 29.60684 -1.57231 0.441282 -3.56304 0.000367 0.049859 
According to the fluorescent in situ hybridization (FISH) analysis, CDK4 gain 
(Figure 11, Panel A) was detected in the 10% of patients at poor prognosis (those 
presenting also CDK4 gain at NGS), while no CDK4 gain was detected in patients 
at good, without a significant difference between the two groups (p=0.5). 
According to the immunohistochemistry (IHC) analysis, nuclear CDK4 
overexpression (score 3+) (Figure 11, Panel B) was detected in the 20% and 7.1% 
of patients at poor and good prognosis, respectively (p=0.62). No association 
between CDK4 gain at NGS and nuclear CDK4 overexpression at IHC (p=1.0) was 
observed. CDK4 gain at FISH and nuclear CDK4 overexpression were more 
frequently associated with poor prognosis, despite a non-statistically significant 
difference, with a similar trend for CDK6 overexpression as well (Figure 11, Panel 
C; Figure 12). Patients with poor prognosis resulted to have a significantly higher 
chance to be cumulatively associated with abnormalities in CDK4/CDK6 overall 
expression or CNV (Figure 13). 
Figure 11. Fluorescent in situ hybridization analysis for CDK4 showing a gain of 
the probe mapping the CDK4 gene locus (Panel A) and immunohistochemistry 
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analysis for nuclear CDK4 (Panel B) and CDK6 (Panel C) showing a strong 
immunoexpression (Score 3+). 
 
Figure 12. Odds Ratio analysis of fluorescent in situ hybridization (Panel A) and 
immunohistochemistry (Panel B) evaluations according to prognosis: an OR<1 
indicates a higher chance to be associated with good prognosis; an OR>1 indicates 
a higher chance to be associated with poor prognosis. OR, odds Ratio; CI, 
confidence interval; FISH, fluorescent in situ hybridization; IHC, 
immunohistochemistry. 
 
Figure 13. Cumulative Odds Ratio analysis of CDK4 (evaluated by next-generation 
sequencing, fluorescent in situ hybridization, and immunohistochemistry analysis) 
including CDK6 (evaluated by immunohistochemistry analysis) [Panel A] or 
excluding CDK6 (Panel B). OR, odds Ratio; CI, confidence interval; FISH, 
fluorescent in situ hybridization; IHC, immunohistochemistry; NGS, next-
generation sequencing. 
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Regarding the sTIL assessment, the median value was 1% (range 0-30%), with only 
6% of cases presenting a TILs percentage ≥10%. No significant association 
(p=0.41) between TILs level (considered as a categorical variable, <1% and ≥1%) 
and prognosis was found (OR 1.75, 95%CI 0.45-6.8, p=0.41). In addition, no 
significant association between TILs level and CDK4 gains was identified 
(p=0.99).  
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DISCUSSION 
Despite the improvements in the understanding of the ILC biology, the prognosis 
of this histotype remains controversial. The ILC still requires the identification and 
validation of a reliable clinical-pathological and molecular portrait, in order to 
stratify early-stage patients according to prognosis. In this regard, the majority of 
evidence regarding the potential prognostic role of proliferation derived from 
patients affected by IDC, and these implications are applied for ILC patients as well. 
This analysis suggests that the prognostic relevance of Ki67 (as well as its optimal 
cut-off) seems to significantly differ according to breast cancer histology. Indeed, 
while a threshold of 15% is indicative of high Ki67 status in IDC patients, a very 
low cut-off of Ki67 (4%-5%) may be able to significantly discriminate the 
prognosis of patients with ‘pure’ ILC. Therefore, these results contribute to support 
to not apply the prognostic Ki67 cut-off of IDC to ILC.  
To date, the lack of reliable biomarkers that can identify those patients who truly 
benefit from cytotoxic agents represents a relevant aspect in the treatment strategy 
of early-stage ILC and early-stage breast cancer in general. In the context of ILC, 
the benefit of adjuvant chemotherapy is still unclear considering that previous 
studies reported no benefit of adjuvant chemotherapy in early ILC [35, 36]. Even 
when analyzed by multigene prognostic signatures, ILC is only rarely considered 
as a high-risk prognosis disease, warranting adjuvant chemotherapy [37-39].  
Our propensity score analysis suggests that patients with pure luminal/HER2-
negative ILC may significantly benefit from the addition of adjuvant chemotherapy 
to hormonotherapy in terms of OS and DDFS, particularly for large and lymph node 
positive tumors. A similar trend was shown for more biologic aggressive tumors, 
defined by high Ki67 and grading. Similar to a recent retrospective study, our results 
highlight that patients with high-risk ILC should not be denied adjuvant 
chemotherapy because of such histologic subtype [40]. 
In the era of cancer molecular profiling, the design and the application of risk 
models based on clinical parameters still provide valuable information for 
clinicians. Moreover, the abundance of genomic analyses does not always translate 
into a clinically meaningful result. Therefore, the most promising approach is likely 
to be represented by an integration of clinical data and genomic-proteomic 
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characterization. The results of this project support the strength of an integrative 
approach, extending from prognostic dichotomization to multi-platform 
genomic/transcriptomic analyses, able to unravel candidate aberrations with a 
biological impact on ILC oncogenesis. In this regard, the combination of clinical-
pathological parameters is able to robustly stratify the prognosis of patients affected 
by early-stage ILC. Moreover, the external validation reinforced the discrimination 
performance of the prognostic model, supporting the ability of this model to 
accurately separate ILC patients into three risk classes according to their individual 
risk of recurrence. Our analysis does not represent a simple investigation of 
prognostic factors for ILC (as previously reported by a series of retrospective 
studies) [41, 42]; the novelty of this study consists in the development and 
validation of a prognostic tool (consisting of the combination of reliable clinical-
pathological factors with different prognostic weight according to the model’s score 
assessment) easy to adopt in the clinical practice. These results may help the 
clinicians to estimate the DFS and OS of early stage ILC, an histotype where several 
aspects (including the prognosis) represent a matter of research for the personalized 
medicine. Indeed, although the common prognostic factors for early-stage BC are 
indiscriminately applied for both lobular and ductal histology, determining that ILC 
patients are substantially treated in the same way as those affected by invasive 
carcinoma of NST, the overall prognosis of the two histotypes appears different [3, 
42]. Thus, this peculiar prognostic aspect supports the hypothesis that specific 
molecular features might drive the ILC prognosis. In this regard, the selection of 
‘exceptional’ responders may increase the likelihood of finding a molecular 
characteristic that could account for the outcome [8].  
Based on this approach, we performed the molecular analysis in an explorative 
subset of ‘worst’ prognostic performers, comparing the results with those of a subset 
of ‘best’ performers. The most intriguing finding we obtained concerns the potential 
negative prognostic role of CDK4 gain, detected by NGS analysis. Moreover, the 
CDK4 amplification, detected by FISH analysis, and the nuclear CDK4 
overexpression displayed a trend toward an association with poor prognosis. As 
expected in the lobular histotype, the most frequent alteration is represented by the 
CDH1 mutation and loss of heterozygosity, without a different distribution in the 
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two prognostic groups. Similarly, mutations in PIK3CA, TP53, CDKN2A and 
FOXA1 are not associated with prognosis. The incidence of FOXA1 mutation and 
ESR1 gain are similar to that reported by Desmedt et al. (11.8% vs. 9% and 35.3% 
vs. 25.3%, respectively) [5]. Considering that FOXA1 plays a key role in the 
endocrine signaling, through the involvement in the estrogen receptor (ER)-
mediated transcription, these gene alterations need to be further explored in the 
context of ILC, where the endocrine therapy represents the main therapeutic 
strategy [43]. The unsupervised clustering analysis of the transcriptome evidenced 
differences between the two prognostic groups in terms of gene expression level. 
Unlike a previous integrative study [4], our analysis showed that a series of genes, 
overexpressed in the poor prognosis group, may play a relevant role in the 
oncogenesis and treatment resistance in BC. For example, the METTL17 interacts 
with both the AF1 and AF2 domains of ERα/β. In a recent study, the observation 
that knockdown of METTL17 reduces BC cell growth suggests that METTL17 
regulates the cancer cell growth possibly through modulation of ERα function as 
well as the expression of ERα/β target genes [44].  
With regard to the presence of sTIL, our analysis showed that the majority of ILCs 
are characterized by low levels of sTIL, without a statistically significant 
distribution between the two prognostic cohorts. These results are consistent with a 
recent analysis reporting that the percentage of sTIL in ILC was lower compared to 
that in invasive carcinoma of NST and that the sTIL level did not represent an 
independent prognostically variable [45].    
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CONCLUSION 
In conclusion, our multi-step analyses suggested that: 1) The already known Ki67 
value of 14% represents a good prognostic cut-off for patients with IDC, while a 
Ki67 value of 4% or 5% discriminates the prognosis of patients affected by ILC; 2) 
Patients affected by luminal ILC could derive significant survival benefit from the 
addition of chemotherapy to hormonotherapy, especially for high-risk patients; 3) 
A risk stratification model able to accurately separate early-stage ILC patients’ 
prognosis into different risk classes, according to clinical-pathological variables, 
allowed to investigate potential biomarkers of prognosis with targeted NGS in an 
explorative cohort. In particular, CDK4 gain is suggested for future validation as a 
prognostic biomarkers and potential therapeutic opportunity. 
The introduction and validation of a personalized approach in the context of ILC 
might allow the clinicians to provide the best available therapy for every individual 
patient to potentiate the expected clinical benefit and reduce the human cost.   
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